Bradley L. Smith

4.4k total citations
39 papers, 1.5k citations indexed

About

Bradley L. Smith is a scholar working on Molecular Biology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Bradley L. Smith has authored 39 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Infectious Diseases and 8 papers in Epidemiology. Recurrent topics in Bradley L. Smith's work include HIV/AIDS Research and Interventions (10 papers), HIV/AIDS drug development and treatment (6 papers) and Protein Kinase Regulation and GTPase Signaling (5 papers). Bradley L. Smith is often cited by papers focused on HIV/AIDS Research and Interventions (10 papers), HIV/AIDS drug development and treatment (6 papers) and Protein Kinase Regulation and GTPase Signaling (5 papers). Bradley L. Smith collaborates with scholars based in United States, Israel and United Kingdom. Bradley L. Smith's co-authors include Daria Mochly‐Rosen, Hanita Khaner, Jamie Lopez Bernal, David L. Rimm, Robert L. Camp, Diane Kowalski, Marisa Dolled‐Filhart, Steve Horvath, Charles L. Sawyers and Eric Kielhorn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Bradley L. Smith

37 papers receiving 1.5k citations

Peers

Bradley L. Smith
George E. Durán United States
Bo‐Sheng Pan United States
Susan Bakke United States
Douglas C. Marchion United States
Salla Keskitalo Finland
Maria Luisa Veronese United States
Franklin C. Harwood United States
Ashish Juvekar United States
Emanuela Colombo Italy
Noel A. Warfel United States
George E. Durán United States
Bradley L. Smith
Citations per year, relative to Bradley L. Smith Bradley L. Smith (= 1×) peers George E. Durán

Countries citing papers authored by Bradley L. Smith

Since Specialization
Citations

This map shows the geographic impact of Bradley L. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bradley L. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bradley L. Smith more than expected).

Fields of papers citing papers by Bradley L. Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bradley L. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bradley L. Smith. The network helps show where Bradley L. Smith may publish in the future.

Co-authorship network of co-authors of Bradley L. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Bradley L. Smith. A scholar is included among the top collaborators of Bradley L. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bradley L. Smith. Bradley L. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Colasanti, Jonathan, Victoria Robinson, Erica Anderson, et al.. (2025). Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. Clinical Infectious Diseases.
2.
Murphy, Thomas J., Jeri Sumitani, Bradley L. Smith, et al.. (2024). Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South. AIDS Research and Human Retroviruses. 40(12). 690–700. 6 indexed citations
3.
Rivera, Christina G., et al.. (2023). HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic. Drugs. 83(18). 1677–1698. 8 indexed citations
4.
5.
Collins, Lauren F., et al.. (2022). Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South. Open Forum Infectious Diseases. 9(9). ofac455–ofac455. 44 indexed citations
6.
Brennan, Meghan B., Jackson Musuuza, Bradley L. Smith, et al.. (2018). 2372. Multidisciplinary Care Teams to Reduce Major Amputations for Patients With Diabetic Foot Ulcers: A Systematic Review. Open Forum Infectious Diseases. 5(suppl_1). S706–S706. 1 indexed citations
7.
Smith, Bradley L., Christina G. Rivera, Ross Dierkhising, et al.. (2018). 1243. Comparative Analysis of Antimicrobial-related Adverse Events in the Outpatient Treatment of Staphylococcal Infections. Open Forum Infectious Diseases. 5(suppl_1). S378–S378. 1 indexed citations
8.
Cardozo, Eden R., et al.. (2010). Utility of an automated notification system for recruitment of research subjects. Emergency Medicine Journal. 27(10). 786–787. 8 indexed citations
9.
Spector, Neil L., Yosef Yarden, Bradley L. Smith, et al.. (2007). Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proceedings of the National Academy of Sciences. 104(25). 10607–10612. 89 indexed citations
10.
Masiello, David, et al.. (2007). Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biology & Therapy. 6(2). 195–201. 20 indexed citations
11.
Wetzel, Randy, et al.. (2005). Evaluation of CML model cell lines and imatinib mesylate response: Determinants of signaling profiles. Journal of Immunological Methods. 305(1). 59–66. 6 indexed citations
12.
Thomas, George, Steve Horvath, Bradley L. Smith, et al.. (2004). Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer. Clinical Cancer Research. 10(24). 8351–8356. 54 indexed citations
13.
Smith, Bradley L., D Chin, Warren Maltzman, et al.. (2004). The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. British Journal of Cancer. 91(6). 1190–1194. 69 indexed citations
14.
Basu, Soumalee, Moumita Basu, Holly V. Goodson, et al.. (2004). Glycosphingolipid metabolism and signaling in apoptotic cancer cells.. 81–100.
15.
Jacobberger, James W., R. Michael Sramkoski, Phyllis S. Frisa, et al.. (2003). Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell‐based measure of Bcr/Abl kinase activity. Cytometry Part A. 54A(2). 75–88. 42 indexed citations
16.
17.
Kielhorn, Eric, Elayne Provost, Thomas G. D'Aquila, et al.. (2002). Tissue microarray‐based analysis shows phospho‐β‐catenin expression in malignant melanoma is associated with poor outcome. International Journal of Cancer. 103(5). 652–656. 51 indexed citations
18.
Smith, Bradley L., et al.. (1996). The HIV Nef Protein Associates with Protein Kinase C Theta. Journal of Biological Chemistry. 271(28). 16753–16757. 95 indexed citations
19.
Smith, Bradley L. & Daria Mochly‐Rosen. (1992). Inhibition of protein kinase C function by injection of intracellular receptors for the enzyme. Biochemical and Biophysical Research Communications. 188(3). 1235–1240. 47 indexed citations
20.
Mochly‐Rosen, Daria, Kenneth G. Miller, Richard H. Scheller, et al.. (1992). p65 Fragments, homologous to the C2 region of protein kinase C, bind to the intracellular receptors for protein kinase C. Biochemistry. 31(35). 8120–8124. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by George E. Durán Breakdown of academic impact, for papers by Bo‐Sheng Pan Breakdown of academic impact, for papers by Susan Bakke Breakdown of academic impact, for papers by Douglas C. Marchion Breakdown of academic impact, for papers by Salla Keskitalo Breakdown of academic impact, for papers by Maria Luisa Veronese Breakdown of academic impact, for papers by Franklin C. Harwood Breakdown of academic impact, for papers by Ashish Juvekar Breakdown of academic impact, for papers by Emanuela Colombo Breakdown of academic impact, for papers by Noel A. Warfel
Rankless by CCL
2026